ERBB2 and breast carcinoma: MEN1611 and taselisib also induced the degradation of the p110α protein in a dose-dependent manner but only in breast cancer cell lines harboring PIK3CA mutations (H1047R and E545K) independently of HER2 status (Fig. 3 A, B).